Literature DB >> 31029218

Paclitaxel.

Fulwah Yahya Alqahtani1, Fadilah Sfouq Aleanizy1, Eram El Tahir1, Hamad M Alkahtani2, Bushra T AlQuadeib1.   

Abstract

Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analysis; Cancer; Paclitaxel; Physicochemical; Taxus

Mesh:

Substances:

Year:  2019        PMID: 31029218     DOI: 10.1016/bs.podrm.2018.11.001

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  19 in total

1.  Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Authors:  Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz
Journal:  Clin Transl Sci       Date:  2022-08-17       Impact factor: 4.438

2.  Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells.

Authors:  Alejandro Español; Yamila Sanchez; Agustina Salem; Jaqueline Obregon; Maria Elena Sales
Journal:  World J Clin Oncol       Date:  2022-06-24

3.  Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.

Authors:  Zhichao Tian; Fan Zhang; Po Li; Jiaqiang Wang; Jinpo Yang; Peng Zhang; Weitao Yao; Xin Wang
Journal:  BMC Cancer       Date:  2020-07-28       Impact factor: 4.430

4.  One-photon red light-triggered disassembly of small-molecule nanoparticles for drug delivery.

Authors:  Kaiqi Long; Han Han; Weirong Kang; Wen Lv; Lang Wang; Yufeng Wang; Liang Ge; Weiping Wang
Journal:  J Nanobiotechnology       Date:  2021-11-04       Impact factor: 10.435

Review 5.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24

Review 6.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110

Review 7.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110

Review 8.  Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy.

Authors:  Jan Škubník; Vladimíra Pavlíčková; Tomáš Ruml; Silvie Rimpelová
Journal:  Plants (Basel)       Date:  2021-03-17

Review 9.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31

10.  Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol.

Authors:  Chunhoo Cheon; Seong-Gyu Ko
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.